Literature DB >> 371539

SCE-963, a new potent cephalosporin with high affinity for penicillin-binding proteins 1 and 3 of Escherichia coli.

Y Nozaki, A Imada, M Yoneda.   

Abstract

A few biochemical activities of SCE-963, a new cephalosporin with potent antibacterial activities against gram-negative bacteria, were compared with those of several currently available cephalosporins against strains of Escherichia coli K-12. The minimum inhibitory concentrations of SCE-963, cefazolin, cephaloridine, cephalothin, and cephalexin were 0.2, 1.56, 3.13, 12.5, and 25 mug/ml, respectively. Affinities of these cephalosporins for the penicillin-binding protein (PBP) 1B of E. coli correlated well with their antibacterial activities; among tested cephalosporins, SCE-963 showed the highest affinity for PBP 1B. SCE-963 inhibited cross-linking of peptidoglycan in a cell-free system the most strongly suggesting that this inhibition results from its high affinity for PBP 1B. SCE-963 also showed the highest affinity for PBP 3; it caused filamentation of cells over a wide range of relatively lower concentrations. Thus its superior antibacterial activity is believed to be manifested through its high affinity for the PBPs.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 371539      PMCID: PMC352594          DOI: 10.1128/AAC.15.1.20

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  16 in total

1.  Mutants of Escherichia coli which lack a component of penicillin-binding protein 1 are viable.

Authors:  B G Spratt; V Jobanputra
Journal:  FEBS Lett       Date:  1977-07-15       Impact factor: 4.124

Review 2.  Interaction of penicillin with the bacterial cell: penicillin-binding proteins and penicillin-sensitive enzymes.

Authors:  P M Blumberg; J L Strominger
Journal:  Bacteriol Rev       Date:  1974-09

3.  Identification of the binding protein which may be the target of penicillin action in Bacillus megaterium.

Authors:  P E Reynolds; S T Shepherd; H A Chase
Journal:  Nature       Date:  1978-02-09       Impact factor: 49.962

4.  A method for measuring the outer membrane-permeability of beta-lactam antibiotics in gram-negative bacteria.

Authors:  T Sawai; K Matsuba; S Yamagishi
Journal:  J Antibiot (Tokyo)       Date:  1977-12       Impact factor: 2.649

5.  Properties of the penicillin-binding proteins of Escherichia coli K12,.

Authors:  B G Spratt
Journal:  Eur J Biochem       Date:  1977-01

6.  Temperature-sensitive cell division mutants of Escherichia coli with thermolabile penicillin-binding proteins.

Authors:  B G Spratt
Journal:  J Bacteriol       Date:  1977-07       Impact factor: 3.490

7.  Thermosensitive mutation in Escherichia coli simultaneously causing defects in penicillin-binding protein-1Bs and in enzyme activity for peptidoglycan synthesis in vitro.

Authors:  S Tamaki; S Nakajima; M Matsuhashi
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

8.  On the process of cellular division in Escherichia coli: a series of mutants of E. coli altered in the penicillin-binding proteins.

Authors:  H Suzuki; Y Nishimura; Y Hirota
Journal:  Proc Natl Acad Sci U S A       Date:  1978-02       Impact factor: 11.205

9.  Mutants of Escherichia coli lacking in highly penicillin-sensitive D-alanine carboxypeptidase activity.

Authors:  M Matsuhashi; Y Takagaki; I N Maruyama; S Tamaki; Y Nishimura; H Suzuki; U Ogino; Y Hirota
Journal:  Proc Natl Acad Sci U S A       Date:  1977-07       Impact factor: 11.205

10.  Function of the outer membrane of Escherichia coli as a permeability barrier to beta-lactam antibiotics.

Authors:  W Zimmermann; A Rosselet
Journal:  Antimicrob Agents Chemother       Date:  1977-09       Impact factor: 5.191

View more
  10 in total

1.  Lateral diffusion of proteins in the periplasm of Escherichia coli.

Authors:  J M Brass; C F Higgins; M Foley; P A Rugman; J Birmingham; P B Garland
Journal:  J Bacteriol       Date:  1986-03       Impact factor: 3.490

2.  In vitro and in vivo antibacterial activities of CS-807, a new oral cephalosporin.

Authors:  Y Utsui; M Inoue; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1987-07       Impact factor: 5.191

3.  Novel morphological changes in gram-negative bacteria caused by combination of bulgecin and cefmenoxime.

Authors:  M Nakao; K Yukishige; M Kondo; A Imada
Journal:  Antimicrob Agents Chemother       Date:  1986-09       Impact factor: 5.191

4.  In vivo interaction of beta-lactam antibiotics with the penicillin-binding proteins of Streptococcus pneumoniae.

Authors:  R Williamson; R Hakenbeck; A Tomasz
Journal:  Antimicrob Agents Chemother       Date:  1980-10       Impact factor: 5.191

5.  Cefotiam therapy of lower respiratory tract infections.

Authors:  M A Polis; C U Tuazon
Journal:  Antimicrob Agents Chemother       Date:  1985-10       Impact factor: 5.191

6.  In vitro and in vivo antibacterial activities of carumonam (AMA-1080), a new N-sulfonated monocyclic beta-lactam antibiotic.

Authors:  A Imada; M Kondo; K Okonogi; K Yukishige; M Kuno
Journal:  Antimicrob Agents Chemother       Date:  1985-05       Impact factor: 5.191

7.  In vitro and in vivo morphological response of Klebsiella pneumoniae to cefotiam and cefazolin.

Authors:  M Nakao; T Nishi; K Tsuchiya
Journal:  Antimicrob Agents Chemother       Date:  1981-05       Impact factor: 5.191

8.  Cefmenoxime (SCE-1365), a novel broad-spectrum cephalosporin: in vitro and in vivo antibacterial activities.

Authors:  K Tsuchiya; M Kondo; M Kida; M Nakao; T Iwahi; T Nishi; Y Noji; M Takeuchi; Y Nozaki
Journal:  Antimicrob Agents Chemother       Date:  1981-01       Impact factor: 5.191

Review 9.  Clinical pharmacokinetics of cefotiam.

Authors:  J M Brogard; F Jehl; B Willemin; A M Lamalle; J F Blickle; H Monteil
Journal:  Clin Pharmacokinet       Date:  1989-09       Impact factor: 6.447

10.  Beta-lactamase stability and antibacterial activity of cefmenoxime (SCE-1365), a novel cephalosporin.

Authors:  K Okonogi; M Kuno; M Kida; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1981-08       Impact factor: 5.191

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.